A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
← catalyst calendarNCT07783425 · readout in 735 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,375estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-19 | estimated | When the study began enrolling |
| Primary completion | 2028-08-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Tilrekimig — also filed as PF-07275315
- Drug: Dupilumab — also filed as Dupixent
- Other: Placebo for Tilrekimig — also filed as Placebo for PF-07275315
- Other: Placebo for Dupilumab
Primary outcomes
what the primary-completion date above is the date OFDifference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus placebo.
measured Week 16
Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus placebo.
measured Week 16
Related
PFE · their whole pipeline · Atopic Dermatitis readouts · Congress trades in PFE · Executive-branch trades in PFE
PFE's other studiesmost recently updated first
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Phase 1 · Recruiting
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments Phase 3 · Recruiting
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Phase 3 · Recruiting
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Phase 3 · Recruiting
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Phase 3 · Recruiting
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed